MALAT1 and plasma cell myeloma: LNA gapmeR ASO-targeting lncRNA MALAT1 possesses anti-multiple myeloma activity (Amodio et al., 2018); (iii) CRISPR/Cas9 technology is suitable for dual-located lncRNAs, and it has been widely used in the discovery and annotation of lncRNAs but, as of yet, is not ideal for systematic drug delivery.